Phathom Pharmaceuticals’ (PHAT) “Buy” Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $28.00 target price on the stock. PHAT has been the topic of several other research reports. Guggenheim restated a “buy” rating on shares of Phathom Pharmaceuticals […]
Needham & Company LLC reiterated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $28.00 target price on the stock. PHAT has been the topic of several other research reports. Guggenheim restated a “buy” rating on shares of Phathom Pharmaceuticals […]
